Clinical Trial Update: One Year Extension Study To Protocol C2/5/TZ:MS-05 [Phase 1, Phase 2]

View source ↗

Summary

One-year extension study to a Phase 1/2 trial (Protocol C2/5/TZ:MS-05) in spasticity associated with multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Spasticity

Snippet

Sponsor: Teva GTC | Conditions: Spasticity, Multiple Sclerosis | Phase 1, Phase 2 | Status: TERMINATED